C.R. Bard (NYSE:BCR) acquired Minneapolis-based angioplasty balloon maker Lutonix Inc. for $325 million.

The merger, announced during Bard’s 2012 guidance update conference call, grants Lutonix $225 million up front with another $100 million when Lutonix achieves pre-market approval for its drug-coated balloons.